Por favor, use este identificador para citar o enlazar este ítem:
http://sgc.anlis.gob.ar/handle/123456789/1739
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Sosa-Estani, Sergio | es |
dc.contributor.author | Segura, Elsa L. | es |
dc.date.accessioned | 2020-11-25T13:56:26Z | - |
dc.date.available | 2020-11-25T13:56:26Z | - |
dc.date.issued | 1999 | - |
dc.identifier.issn | 1678-8060 | - |
dc.identifier.uri | http://sgc.anlis.gob.ar/handle/123456789/1739 | - |
dc.description | Fil: Sosa Estani, Sergio. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación de Endemo-Epidemias; Argentina. | es |
dc.description | Fil: Segura, Elsa Leonor. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación de Endemo-Epidemias; Argentina. | es |
dc.description.abstract | The goals of specific treatment against Trypanosoma cruzi infection, at an individual level, are to eliminate the parasite, to diminish the probability of developing illness (Chagas disease), and to hinder the chain of T. cruzi transmission as actions for the control of vectorial and non vectorial transmission (Sosa Estani 1993). Around 1930, investigations began in Argentina to obtain an effective drug against T. cruzi. Of all the substances evaluated, only nifurtimox (1972) and benznidazol (1974) have been accepted by the Ministry of Health as anti-T. cruzi drugs. Both drugs began to be assessed on the acute phase, and later, on the chronic phase of the disease | es |
dc.format | - | |
dc.language.iso | en | es |
dc.relation.ispartof | Memorias do Instituto Oswaldo Cruz | es |
dc.rights | Open Access | - |
dc.rights | Creative Commons Attribution 3.0 International License | - |
dc.rights.uri | https://creativecommons.org/licenses/by/3.0/deed.es | - |
dc.source | Memorias do Instituto Oswaldo Cruz 1994; 94(1):363-365 | - |
dc.subject | Trypanosoma cruzi | es |
dc.subject | Terapéutica | es |
dc.subject | Argentina | es |
dc.title | Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina | es |
dc.type | Artículo | es |
dc.identifier.doi | 10.1590/s0074-02761999000700070 | - |
anlis.essnrd | 1 | - |
item.fulltext | With Fulltext | - |
item.openairetype | Artículo | - |
item.grantfulltext | open | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS) | - |
crisitem.author.dept | Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS) | - |
crisitem.author.dept | Instituto Nacional de Parasitología (INP) | - |
crisitem.author.parentorg | Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS) | - |
Aparece en las colecciones: | Publicaciones CeNDIE |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
5900.pdf | Artículo en inglés | 71.45 kB | Adobe PDF | Visualizar/Abrir |
Visualizaciones de página(s)
61
comprobado en 15-ago-2025
Descarga(s)
7
comprobado en 15-ago-2025
Google ScholarTM
Consultar
Altmetric
Altmetric
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons